Please login to the form below

Not currently logged in
Email:
Password:

David Horn Solomon takes the helm of Akari Therapeutics

He joins as its chief executive officer

Akari Therapeutics has appointed David Horn Solomon as its new chief executive officer, a role that will see him take the helm of the biopharma as it focuses on the development and commercialisation of orphan autoimmune and inflammatory disease treatments.

Ray Prudo, Akari's executive chairman, said: “I am very pleased that David will be joining Akari and that we have been successful in attracting a person of his calibre, with over 20 years of leadership experience in the biotechnology field.

“David has a strong track record of leading phase II stage companies like Akari, most notably at Zealand Pharma where he led the development of lixisenatide, which is now commercialised by Sanofi.”

His other roles have included CEO at Bionor Pharma and most recently he was at Nordic healthcare investment group Sund Capital where he was a managing partner.

Solomon, who will be based at the group’s headquarters in New York, said: “I am excited by Akari’s growing and diversified discovery platform and its clinical programmes in the complement mediated diseases.

“Akari is building momentum in its research programmes and this is a hugely exciting time to join and help advance its products.”

3rd October 2017

From: Sales

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Six Degrees Medical Consulting

For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...

Latest intelligence

DATA shutterstock_1818502577-640.jpg
Empowering patients empowers results
Patient-centricity is key when it comes to creating a more flexible, efficient and modern process for clinical trials...
Don’t limit diversity to just representation in clinical trials
What is the power of diversity in the healthcare environment? Can it make clinical trials more inclusive?...
Oh no… not more training
Paul Hutchings, founder of fox&cat, discusses ways to help your team manage pressure in a more human, pressure-centric and engaging way...

Infographics